213 related articles for article (PubMed ID: 18815451)
1. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.
Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
Neuroepidemiology; 2008; 31(3):193-200. PubMed ID: 18815451
[TBL] [Abstract][Full Text] [Related]
2. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients.
Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
Alzheimer Dis Assoc Disord; 2008; 22(2):125-30. PubMed ID: 18525283
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
[TBL] [Abstract][Full Text] [Related]
4. [The elderly, sleep habits and use of psychotropic drugs by the French population].
Ohayon M; Caulet M; Lemoine P
Encephale; 1996; 22(5):337-50. PubMed ID: 9035990
[TBL] [Abstract][Full Text] [Related]
5. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
Tifratene K; Duff FL; Pradier C; Quetel J; Lafay P; Schück S; Benzenine E; Quantin C; Robert P
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):1005-12. PubMed ID: 22718684
[TBL] [Abstract][Full Text] [Related]
6. [Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey].
Grolleau A; Cougnard A; Bégaud B; Verdoux H
Encephale; 2008 Sep; 34(4):352-9. PubMed ID: 18922237
[TBL] [Abstract][Full Text] [Related]
7. Direct costs of Alzheimer's disease in Germany.
Kiencke P; Daniel D; Grimm C; Rychlik R
Eur J Health Econ; 2011 Dec; 12(6):533-9. PubMed ID: 20640868
[TBL] [Abstract][Full Text] [Related]
8. [Cost of illness in Alzheimer's disease].
Kiencke P; Rychlik R; Grimm C; Daniel D
Med Klin (Munich); 2010 May; 105(5):327-33. PubMed ID: 20503006
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic dose-sparing effect with addition of memantine.
Sleeper RB
Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
[TBL] [Abstract][Full Text] [Related]
10. [Pharmaco-therapeutic evaluation of medical treatments of adult autistics and multi-handicapped patients in a public mental health unit].
Armand-Branger S; Poisson N; Gaudoneix-Taïeb M; Ramos O
Encephale; 2009 Sep; 35(4):370-6. PubMed ID: 19748374
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.
Pariente A; Pinet M; Moride Y; Merlière Y; Moore N; Fourrier-Réglat A
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):680-6. PubMed ID: 20583209
[TBL] [Abstract][Full Text] [Related]
12. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Agüera-Ortiz LF;
Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
14. Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.
Paskavitz JF; Gunstad JJ; Samuel JE
Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):454-9. PubMed ID: 17267379
[TBL] [Abstract][Full Text] [Related]
15. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
Lachaine J; Beauchemin C; Crochard A; Bineau S
Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland.
Gobert M; D'hoore W
Int J Geriatr Psychiatry; 2005 Aug; 20(8):712-21. PubMed ID: 16035123
[TBL] [Abstract][Full Text] [Related]
17. Transition in care in persons with antidepressant prescription in naturalistic conditions.
Verdoux H; Gaudron Y; Tournier M
Fam Pract; 2011 Aug; 28(4):400-5. PubMed ID: 21398386
[TBL] [Abstract][Full Text] [Related]
18. [Use of specific drugs for Alzheimer's disease].
Villar Fernández I; Rabaneque Hernández MJ; Armesto Gómez J; García Arilla E; Izuel Rami M
Neurologia; 2007 Jun; 22(5):275-84. PubMed ID: 17508301
[TBL] [Abstract][Full Text] [Related]
19. [Alzheimer dementia. Memantine: value for patient and caregivers].
MMW Fortschr Med; 2009 Nov; 151(45):44-5. PubMed ID: 19960725
[No Abstract] [Full Text] [Related]
20. [Memantine for the treatment of dementia].
van Gool WA; Eikelenboom P
Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2101-2. PubMed ID: 14619198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
